Top priority for the IPO proceeds will be MZE829, an oral APOL1 inhibitor being tested for APOL1 kidney disease, with dosing in an ongoing phase 2 expected to begin in the coming weeks.
HealthDay on MSN10d
Tea Consumption Can Lower Mortality in Chronic Kidney DiseaseTea consumption offers protective effects on mortality among patients with chronic kidney disease, according to study findings.
A growing body of evidence links use of proton pump inhibitors to kidney problems, including kidney failure in patients with existing CKD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback